RxDoctor Payments DataLook up a doctor →

Sidharth Shah

Clinical Cardiac Electrophysiology · Raleigh, NCNPI 1184840688

Payments from drug & device makers

$516,983in general payments, 2019–2025

Across 413 payments — averaging $1251.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$423K
  • Abbott$79K
  • Medtronic$6K
  • Cordis US CORP.$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Pfizer$2K
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$29,90054%
  • Speaking & faculty fees$11,70021%
  • Grants$1000%
  • Travel & lodging$5,24510%
  • Food & beverage$8,18315%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$516,983 in reported general payments places this provider in the 95th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

See all clinical cardiac electrophysiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$515,216
Medicare patients
1,499
Services billed
7,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$228,989
XareltoRivaroxaban35$36,362
Dofetilide38$12,455
Flecainide Acetate78$2,711
Metoprolol Succinate159$1,817
Amiodarone Hcl46$1,132
SotalolSotalol Hcl41$779
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$462
Diltiazem Hcl13$319
Ranolazine ErRanolazine13$315
Metoprolol Tartrate71$309
Carvedilol40$269
Furosemide20$262
Losartan Potassium16$235
Torsemide14$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,314$228,989275 claims
Johnson & JohnsonXarelto$11$36,36235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

Other clinical cardiac electrophysiology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →